Soluble extracellular matrix composition and method for intravascular delivery

A soluble ECM composition, prepared by enzymatic digestion and fractionation, addresses the limitations of current ECM therapies by enabling intravascular delivery and promoting tissue repair and angiogenesis, effectively treating ischemic injuries.

JP2024166198AActive Publication Date: 2024-11-28RGT UNIV OF CALIFORNIA
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024129889
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-10-25
Filing Date
2024-08-06
Publication Date
2024-11-28
Estimated Expiration
2039-10-25

AI Technical Summary

Technical Problem

Current extracellular matrix (ECM) therapies are limited to patches or direct injections and are not suitable for intravascular delivery due to the presence of insoluble components that can leak from the bloodstream and fail to address ischemic injuries like myocardial infarction effectively.

Method used

A method to prepare a soluble ECM composition by enzymatic digestion with acid proteases, followed by pH neutralization and fractionation to separate soluble and insoluble fractions, allowing for intravascular delivery and coating of leaky vasculature.

Benefits of technology

The soluble ECM composition effectively coats and fills leaky vasculature, promoting tissue repair, angiogenesis, and reducing negative left ventricular remodeling post-myocardial infarction, with potential applications in treating various ischemic and endothelial cell-related conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024166198000001_ABST
    Figure 2024166198000001_ABST
Patent Text Reader

Abstract

To provide a soluble extracellular matrix composition and a method for intravascular delivery.SOLUTION: Compositions and methods for manufacturing and using the same are provided. The compositions comprise a soluble extracellular matrix fraction for intravascular delivery which forms a gel or coating in situ for treatment of myocardial infarction and ischemia in a variety of tissues and endothelial injury / dysfunction.SELECTED DRAWING: Figure 7
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Application No. 62 / 750,303, filed October 25, 2018, which is incorporated herein by reference.

[0002] Government support This invention was made with Government support under Grant No. HL113468 awarded by the National Institutes of Health (NIH). The Government has certain rights in the invention.

[0003] The present invention relates to injectable soluble extracellular matrix compositions and treatments for minimally invasive delivery to tissues / organs / cells, including ischemic or injured heart, brain, skeletal muscle, blood vessels, and endothelial cells. [Background technology]

[0004] Extracellular matrix therapies contain natural tissue components that provide a scaffold for tissue regeneration. Current decellularized extracellular matrix therapies are limited to patches or direct injections. No extracellular matrix therapies are capable of intravascular / injection delivery to the tissue of interest. ECM hydrogels made from decellularized and digested tissues have been created, but they are not fully soluble or transparent colloids. They are translucent suspensions that contain both soluble and insoluble components (Freytes et al., 2008, Singelyn et al., 2009)) that allow the material to pass from the bloodstream through leaky vasculature (occurring in ischemic tissues such as acute myocardial infarction, stroke, and cancer) (Nguyen et al., 2015, Dvorak et al., 1988, Yuan et al., 1995)) and into the tissue, lining the leaky vasculature or preventing it from filling the pores of the leaky vasculature.

[0005] Myocardial infarction (MI) is characterized by progressive ischemic necrosis of the myocardium over time, leading to negative left ventricular (LV) remodeling and eventual heart failure. Current standard of care does not address this ischemic injury. Minimally invasive tissue engineering therapies can repair the heart after MI. Many stem cell and growth factor therapies have made it to clinical trials; however, these therapies have shown limited efficacy, possibly due to poor retention of unencapsulated therapeutics.

[0006] Extracellular matrix (ECM) hydrogels have shown great promise in the field of cardiac tissue engineering. In particular, tissue-specific hydrogels derived from decellularized porcine myocardium, termed myocardial matrix (MM), have shown increased myocardial mass, vascularization of the infarcted area, and improved regional and global cardiac function in MI models [2–4]. Furthermore, investigation of the mechanisms of repair through whole-transcriptome analysis of RNA isolated from the infarcted area of ​​MM-injected rat hearts showed upregulated pathways related to cardiac repair (e.g., angiogenesis and cardiac development) and downregulated pathways related to negative LV remodeling (e.g., hypertrophy, apoptosis, and fibrosis) [6]. This material was evaluated in a phase I study in post-MI patients using transendocardial injections 60 days to 3 years after MI (ClinicalTrials.gov identifier: NCT02305602). However, myocardial cell death and negative LV remodeling are processes that begin within minutes to days after MI [26, 27]. Current delivery of MM is limited to transendocardial catheter injections, as it contains submicron particles that are too large to pass through the leaky coronary vasculature and enter the infarct, making it unsuitable for intracoronary infusion. Furthermore, transendocardial injection is a specialized medical technique with several safety concerns of ventricular rupture and arrhythmias within the first week after MI [7, 8]. This prevents delivery of MM within the critical therapeutic window after acute MI.

[0007] Intracoronary injection is an alternative approach to transendocardial injection. Intracoronary delivery is feasible in acute MI as it may involve balloon angioplasty, which is typically performed immediately after the patient is admitted to the hospital. Such techniques are standard in interventional cardiology and do not require specialized training. Intracoronary injection takes advantage of the leaky vasculature after acute MI, allowing biomaterials to pass through the coronary vasculature and enter the infarcted area [5]. Intracoronary delivery of biomaterials has shown the feasibility of alginate hydrogel in a porcine MI model [9] and progressed to a phase II clinical trial (ClinicalTrials.gov identifier: NCT01226563). However, the material did not show significant improvement in cardiac function, possibly due to the limited bioactivity of alginate

[10] . Summary of the Invention

[0008] In an embodiment, the invention provides a method of preparing a soluble extracellular matrix (ECM) composition comprising enzymatically digesting ECM material with an acidic protease, such as pepsin, neutralizing the digested ECM material in a liquid to a pH of 7.0-8.0, processing the liquid ECM to generate soluble and insoluble fractions, and separating at least a portion of the soluble fraction from the insoluble fraction to obtain a soluble ECM composition.

[0009] In embodiments, the invention provides that processing of the liquid ECM to generate soluble and insoluble fractions is accomplished by centrifugation. In embodiments, the invention provides that the soluble ECM composition is dialyzed and / or filtered to remove insoluble material. In embodiments, the invention provides that the soluble ECM composition is further lyophilized for storage and rehydrated for use.

[0010] In an embodiment, the soluble ECM composition is substantially isolated from the ECM solids in the liquid ECM. In an embodiment, the soluble ECM composition is more transparent than the digested unseparated ECM material. In an embodiment, the soluble ECM composition comprises a transparent ECM colloid that can pass through a 0.25 μm filter.

[0011] In an embodiment, the present invention provides a method of treating a subject in need thereof, comprising administering to the subject an effective amount of a soluble ECM composition to promote tissue repair or cell recruitment. In an embodiment, the injection is performed intravenously or intravascularly via a catheter. In an embodiment, the present invention provides that the soluble fraction forms a gel in tissue when delivered in vivo. In an embodiment, the soluble fraction coats the inner lining of blood vessels. In an embodiment, the soluble fraction fills pores, fenestrations, endothelial disruptions, open intercellular junctions, or gaps in leaky or damaged vasculature.

[0012] In embodiments, the invention provides that the soluble fraction of the ECM is further cross-linked with glutaraldehyde, formaldehyde, bis-NHS molecules, or other cross-linking agents. In embodiments, the invention provides that the soluble fraction of the ECM is combined and / or cross-linked with synthetic polymers or biologically derived materials. In embodiments, the invention provides that the soluble fraction of the ECM is combined with cells, peptides, proteins, DNA, drugs, nanoparticles, antibiotics, growth factors, nutrients, survival-promoting additives, proteoglycans, and / or glycosaminoglycans.

[0013] In an embodiment, the present invention provides that the soluble fraction of ECM is used in combination with the above components for endogenous cell growth, angiogenesis, and regeneration. In an embodiment, the present invention provides that the soluble fraction of ECM is used in combination with the above components as a matrix to change the mechanical properties of tissue. In an embodiment, the present invention provides that the soluble fraction of ECM is delivered with cells, alone or in combination with the above components, to regenerate or repair damaged tissue.

[0014] In embodiments, the invention provides that after concentration adjustment and / or sterile filtration, the soluble fraction of the ECM can be lyophilized and stored frozen (e.g., at 20° C., −80° C.) for at least three months. The soluble ECM composition or fraction can then be resuspended and / or sterile filtered prior to injection or infusion.

[0015] In embodiments, the invention provides that after concentration adjustment and / or sterile filtration, the soluble fraction of the ECM can be lyophilized and stored in a refrigerator (e.g., at 4° C.) for at least 3 months. The soluble ECM fraction can then be resuspended and / or sterile filtered prior to injection or infusion.

[0016] In embodiments, the invention provides that after concentration adjustment and / or sterile filtration, the soluble fraction of the ECM can be lyophilized and stored at room temperature for at least three months. The soluble ECM fraction can then be resuspended and / or sterile filtered prior to injection or infusion.

[0017] In an embodiment, the present invention provides that the method of separating at least a portion of the soluble and insoluble fractions of the liquid extracellular matrix (pre-gel solution) can be performed by high speed centrifugation, dialysis, filtration, or pH or salt adjustment. In an embodiment, the separation of the soluble fraction is performed by removing at least a portion of the solids from the ECM material. In an embodiment, the separation of the soluble fraction is performed using a filter having a size limit of less than 1 μm, 0.5 μm, 0.25 μm, 0.22 μm, or 0.2 μm. In an embodiment, the present invention provides a soluble ECM composition derived from decellularized tissue and processed to isolate the soluble fraction before gelling in vivo. In an embodiment, the present invention provides that the composition of soluble ECM is prepared for intravascular injection.

[0018] In embodiments, the present invention provides that the soluble extracellular matrix compositions are derived from human, animal, embryonic and / or fetal tissue sources, hi embodiments, the present invention provides that the soluble extracellular matrix compositions are derived from heart, brain, bladder, small intestine, skeletal muscle, kidney, liver, lung, blood vessels, and other tissue / organ tissue sources.

[0019] In an embodiment, the present invention provides a method for treating acute myocardial infarction comprising injecting or infusing an effective amount of a composition comprising a soluble decellularized extracellular matrix derived from muscle tissue into a subject in need thereof having a myocardial infarction.

[0020] In embodiments, the invention provides that the soluble ECM composition is delivered into a blood vessel by injection. In embodiments, the invention provides that the soluble ECM composition is delivered by intracoronary injection using a balloon infusion catheter. In embodiments, the invention provides that the soluble ECM composition transitions into a gel form within tissue after delivery. In embodiments, the invention provides that the soluble ECM composition transitions to form a coating on the endothelium of an injured blood vessel after delivery. In embodiments, the invention provides that the soluble ECM composition degrades within 1-14 days after injection or infusion.

[0021] In an embodiment, the invention provides that injection or infusion of the composition repairs damage to the heart muscle sustained by the subject, such as a myocardial infarction. In an embodiment, the invention provides that injection or infusion of the composition is used to treat muscle or nerve damage caused by disease, trauma, stroke and / or ischemia in the subject. In an embodiment, the invention provides that the effective amount is an amount that increases blood flow, increases viable tissue mass, or induces new blood vessel formation in the area of ​​injection or infusion in the subject. In an embodiment, the invention provides that the effective amount is an amount that promotes cell survival, reduces inflammation, and repairs damaged vasculature in the area of ​​injection or infusion in the subject. [Brief description of the drawings]

[0022] [Figure 1] Generation of soluble myocardial matrix. Figure 1A shows isolated left ventricular myocardium being cut into small pieces. Figure 1B shows decellularization after continuous stirring in 1% sodium dodecyl sulfate. Figure 1C shows freeze-drying and grinding into a fine powder. Figure 1D shows partially digested myocardial matrix. (E) Fractionated myocardial matrix after centrifugation, (1) the SolMM fraction in the supernatant, and (2) the insoluble pellet. (F) SolMM hydrogel after subcutaneous injection. Images (A-D) were taken from [3]. [Diagram 2]PAGE comparing protein distribution in ladder (Full-Range RPN800E, lane 1), collagen (lane 2), myocardial matrix (lane 3), and soluble myocardial matrix (lane 4) is shown. [Diagram 3] Distribution and retention of SolMM (red greyscale) 12 hours after intracoronary injection of 200 μL of 10 mg / mL SolMM in an ischemia-reperfusion rat model. (Left) Short axis image of an infarcted heart stained with hematoxylin and eosin, with the infarct extending to the lower half of the heart, scale bar 3 mm. (Right) Inset of infarcted myocardium displaying SolMM microscale gels throughout the infarcted myocardium, scale bar 200 μm. [Figure 4] Distribution and retention of SolMM (red greyscale) 1 hour after intracoronary injection in a porcine ischemia-reperfusion model. (Left) Macroscopic short-axis histology of an infarcted porcine heart. The infarct is outlined in blue greyscale. (Right) Infarcted myocardium displaying SolMM microgels throughout the infarcted myocardium. [Diagram 5] Figure 1 shows mitigated negative left ventricular remodeling (preserved EDV and ESV) after intracoronary infusion of SolMM in an ischemia-reperfusion model 24 h and 5 weeks after infusion. EDV-end diastolic volume, ESV-end systolic volume, EF-ejection fraction, SolMM (blue greyscale squares), saline (red greyscale circles). N=10-11 per group. [Figure 6] Increased infarct arteriole density in SolMM-injected rats 5 weeks after infusion and ischemia-reperfusion. Arterioles were identified by co-staining for alpha-smooth muscle actin and isolectin and traced manually in ImageJ. N=10-11 per group. [Figure 7] Figure 1 shows reduced cardiomyocyte apoptosis in the infarct border zone of SolMM-injected rats 3 days after injection and ischemia-reperfusion. Tissues were stained with α-actinin for cardiomyocytes and cleaved caspase 3 for apoptosis. Apoptotic cardiomyocytes were counted manually in ImageJ. N=5-6 per group. [Figure 8]Relative gene expression changes in SolMM-injected rats 1 day after injection and ischemia-reperfusion are shown. Gene expression was measured by RT-qPCR using RNA isolated from the LV free wall. Gene expression at day 1 suggests increases in angiogenic and reactive oxygen species metabolic pathways. N=5-6 per group. [Figure 9] Relative gene expression changes in SolMM-injected rats at 3 days after injection and after ischemia-reperfusion are shown. Gene expression was measured by RT-qPCR using RNA isolated from the LV free wall. Gene expression at day 3 suggests a decrease in apoptosis / necrosis and fibrosis pathways. LRG1 has been implicated in angiogenesis pathways and downregulation of LRG1 is implicated in fibrosis. N=5-6 per group. [Figure 10] Confocal images of soluble matrix (red grayscale) and isolectin (green grayscale) on endothelial cells after soluble matrix injection in an ischemia-reperfusion rat model. Panels are consecutive images from a z-stack. Although soluble matrix coats the inside of small (~5um diameter) capillaries, soluble matrix does not completely occlude the lumen. [Figure 11] Confocal images of soluble matrix (red grayscale) and isolectin (green grayscale) on endothelial cells after soluble matrix injection in an ischemia-reperfusion rat model are shown. The soluble matrix overlaps with the endothelial cells and does not occlude the lumen of the blood vessel. [Figure 12] Figure 1 shows the retention of soluble matrix in soluble matrix-injected hearts 24 hours after injection and ischemia-reperfusion. From left to right, hearts were injected with 1) saline, 2) 10 mg / ml soluble matrix conjugated with Vivo Tag750, 3) 10 mg / ml trilysine conjugated with Vivo Tag750, and 4) 10 mg / ml soluble matrix conjugated with Vivo Tag750. Trilysine was used as a small peptide control and showed minimal cardiac retention. [Figure 13]Scanning electron microscopy images of soluble matrix hydrogels are shown, scale bar 20 μm in left image, scale bar 5 μm in right image. [Figure 14] Dynamic light scattering data for soluble matrix (SolMM) and complete matrix (MM) at 1:50 dilution (1.0 mg / ml and 0.6 mg / ml, respectively) are shown, showing that the soluble matrix particles are less than 100 nm in diameter, whereas the complete matrix has larger particles. [Figure 15] Dynamic light scattering data for soluble matrix (SolMM) at 1:10 and 1:100 dilutions (1.0 mg / ml and 0.1 mg / ml, respectively) are shown, showing particles less than 100 nm in diameter. [Figure 16] Absorbance (left) and transmittance (right) of saline, soluble matrix (SolMM), and complete matrix (MM) are shown. [Figure 17] Relative absorbance (left) and transmittance (right) of soluble matrix (SolMM) and complete matrix (MM) are shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0023] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

[0024] Unless otherwise defined, all technical and scientific terms and any acronyms used herein have the same meaning as commonly understood by one of ordinary skill in the art of the invention. Although any methods and materials similar or equivalent to those described herein can be used in the practice of the invention, exemplary methods, devices, and materials are described herein.

[0025] The practice of the present invention employs, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of those in the art. Such techniques are described in Molecular Cloning: A Laboratory Manual, 2 nd (Sambrook et al., 1989), Oligonucleotide Synthesis (MJGait, ed., 1984), Animal Cell Culture (RIFreshney, ed., 1987), Methods in Enzymology (Academic Press, Inc.), Current Protocols in Molecular Biology (FMAusubel et al., eds., 1987, and periodic updates), PCR: The Polymerase Chain Reaction (Mullis et al., eds., 1994), Remington, The Science and Practice of Pharmacy, 20 th ed., (Lippincott, Williams & Wilkins 2003), and Remington, The Science and Practice of Pharmacy, 22 th ed., (Pharmaceutical Press and Philadelphia College of Pharmacy at University of the Sciences 2012), among others.

[0026] In an embodiment, the present invention provides a method of preparing one or more biologically active soluble fractions of an extracellular matrix (ECM) for therapeutic delivery, comprising the steps of: a. partially or completely digesting a decellularized ECM prepared from a tissue with an acid protease such as pepsin; b. neutralizing the digested ECM material to a pH of 7.0-8.0; c. treating the liquid ECM (pre-gel solution) to generate soluble and insoluble fractions; d. separating at least a portion of the insoluble fraction from the soluble fraction to obtain a soluble ECM composition.

[0027] In embodiments, the invention provides that the soluble ECM composition is further lyophilized, dialyzed, and / or filtered, hi embodiments, the invention provides that the soluble ECM composition is rehydrated after lyophilization.

[0028] In embodiments, the present invention provides a method of treating a subject in need thereof comprising administering to the subject an intravascular injection of an effective amount of a soluble ECM composition to promote organ, tissue, or cell repair or cell mobilization. In embodiments, the injection is administered intravenously or intravascularly via a catheter. In embodiments, the present invention provides that the soluble ECM composition forms a gel in and / or around the microvasculature of the tissue when delivered in vivo.

[0029] In an embodiment, the present invention provides a method for treating acute myocardial infarction comprising injecting or infusing an effective amount of a composition comprising a soluble decellularized extracellular matrix derived from muscle tissue into a subject in need thereof having a myocardial infarction.

[0030] In an embodiment, the present invention provides that the composition is delivered intravascularly. In an embodiment, the present invention provides that the composition is delivered by a balloon infusion catheter. In an embodiment, the present invention provides that the composition transitions to a gel form within tissue after delivery. In an embodiment, the present invention provides that the composition degrades within 1-14 days after injection or infusion. In an embodiment, the present invention provides that injection or infusion of the composition repairs damage to myocardium sustained by the subject. In an embodiment, the present invention provides that injection or infusion of the composition repairs damage to non-cardiac tissue caused by trauma or ischemia in the subject.

[0031] In embodiments, the invention provides that an effective amount is an amount that increases blood flow, increases the amount of viable tissue, or induces new blood vessel formation in the area of ​​injection or infusion in a subject.

[0032] For human treatment, there are many source species of extracellular matrix: for example, human, porcine, bovine, goat, mouse, rat, rabbit, chicken, and other animal sources. In addition, there are many tissue sources: for example, heart, brain, bladder, small intestine, skeletal muscle, kidney, liver, lung, blood vessels, and other tissues and organs.

[0033] In an embodiment, the tissue is first decellularized, leaving only the extracellular matrix, for example as disclosed in US Patent Publication No. US2013 / 0251687, which is incorporated by reference in its entirety. The matrix is ​​then lyophilized, crushed or pulverized, solubilized with pepsin or other enzymes, and then neutralized and buffered as previously reported. After neutralization, the digest (pregel solution) is fractionated to separate soluble and insoluble fractions. The process of separating the soluble and insoluble fractions can be accomplished by centrifugation, dialysis, filtration, or pH or salt adjustment. The soluble fraction can be dialyzed to remove salts, lyophilized, and resuspended to adjust the ECM concentration. The ECM can be sterile filtered, lyophilized, and stored in a sterile container. The ECM can be resuspended to the appropriate / physiological concentration for injection.

[0034] Soluble ECM composition refers to extracellular matrix material that has been decellularized, lyophilized, ground, and digested to remove at least a portion of the solid components. In an embodiment, the soluble ECM composition is obtained from a centrifugation supernatant. In an embodiment, the soluble ECM composition can pass through a filter size of less than 1 μm, 500 nm, 250 nm, 220 nm, or 200 nm. A soluble ECM composition from which at least a portion of the naturally occurring solid ECM components have been removed is a more transparent material than before the ECM solids were removed. However, it should be understood that some insoluble small particulate matter, such as ECM colloids, may still be present in the soluble ECM composition. A soluble ECM composition is substantially isolated when at least 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99% by volume of the naturally occurring ECM solids have been removed.

[0035] After concentration adjustment and / or sterile filtration, the soluble ECM composition can be lyophilized and stored (e.g., at -20°C, -80°C) for at least 3 months. The soluble ECM composition can then be rehydrated with sterile water prior to injection or infusion.

[0036] The soluble ECM composition can be injected through a catheter, delivered intravenously, or by intravascular infusion with or without a balloon. The soluble ECM composition can pass through damaged and leaky vasculature such as that found in acute myocardial infarction, stroke, other ischemic tissues, tumors, etc. Once in the tissue, the soluble ECM composition forms a gel.

[0037] The soluble ECM compositions can be injected through a catheter, delivered intravenously, or by intravascular infusion with or without a balloon. The soluble ECM compositions can assemble to build up a coating on or fill the pores of the lining of leaky vasculature such as those found in acute myocardial infarction, stroke, other ischemic tissues, tumors, tissues suffering from trauma, etc.

[0038] The soluble ECM composition gel can be crosslinked with glutaraldehyde, formaldehyde, bis-NHS molecules, or other crosslinkers. The soluble ECM composition can be combined with cells, peptides, proteins, DNA, drugs, nutrients, survival-promoting additives, proteoglycans, and / or glycosaminolycans. The soluble ECM composition can be combined and / or crosslinked with synthetic polymers. The soluble ECM composition can be used alone or in combination with the above components for endogenous cell growth, vascularization, and regeneration. The soluble ECM composition can be used alone or in combination with the above components as a matrix to change the mechanical properties of tissue. The soluble ECM composition can be delivered with cells alone or in combination with the above components to regenerate damaged tissue.

[0039] The soluble ECM compositions can be used for tissue repair following tissue injury from myocardial infarction, stroke, traumatic brain injury, peripheral arterial disease, hepatic kyphosis, cancerous tumors, or renal injury, etc. The soluble ECM compositions can be used alone or can act as a therapeutic drug delivery vehicle.

[0040] The present invention provides soluble ECM compositions and methods for treating conditions involving endothelial cell damage or dysfunction, leaky vasculature, disruption of endothelial cell junctions, inhibition of vasodilation, and inflammation.

[0041] The present invention provides soluble ECM compositions and methods for treating conditions with potential reperfusion injury, including myocardial infarction, stroke, and peripheral arterial and vascular disease. The soluble ECM compositions can act as tissue engineering scaffolds to reduce reperfusion injury, decrease apoptosis, and promote tissue repair.

[0042] The present invention provides soluble ECM compositions and methods for treating excessive or persistent reactive oxygen species (ROS) production / signaling that leads to endothelial cell activation and inflammation. The soluble ECM compositions can protect cells and tissues from ROS damage and inflammation through physical shielding and / or ROS sequestration.

[0043] The present invention provides soluble ECM compositions and methods for treating cardiac disease, ischemia, and perfusion. The soluble ECM compositions can promote angiogenesis and increase tissue perfusion.

[0044] The present invention provides a soluble ECM composition and method for treating diabetes, insulin resistance, and can treat endothelial cells and restore endothelium-dependent vasodilation.

[0045] The present invention provides soluble ECM compositions and methods for treating cancer, including tumor growth and metastasis. The soluble ECM compositions can treat leaky blood vessels and endothelial dysfunction present in cancer. ECM degradation products have been shown to inhibit tumor growth and formation.

[0046] The present invention provides soluble ECM compositions and methods for treating pulmonary diseases such as chronic obstructive pulmonary disease, asthma, pulmonary arterial hypertension, etc. The soluble ECM compositions can be injected to treat damaged tissue and / or endothelial cells in the lungs.

[0047] The present invention provides soluble ECM compositions and methods for treating chronic renal failure. The soluble ECM compositions can treat blood vessels to restore vasodilation and constriction.

[0048] The present invention provides a soluble ECM composition and method for the treatment of venous thrombosis. Injection of the soluble ECM composition can coat blood vessels to prevent thrombosis and platelet aggregation.

[0049] The present invention provides soluble ECM compositions and methods for treating diseases in which the endothelial barrier is disrupted, such as severe infectious diseases, particularly hemorrhagic fever viruses, including Dengue hemorrhagic fever and Hantavirus pulmonary syndrome. Injection of the soluble matrix can treat and restore the endothelial barrier.

[0050] The present invention provides a soluble ECM composition and method for treating atherosclerosis. Injection of the soluble ECM composition can coat and stabilize atherosclerotic plaques to prevent plaque rupture, or attach to endothelial cells to reduce inflammation.

[0051] The present invention provides a soluble ECM composition and method for treating liver cirrhosis, acute liver failure. The soluble ECM composition can treat endothelial dysfunction in liver cirrhosis. The soluble ECM composition can reduce inflammation and oxidative stress.

[0052] The present invention provides a soluble ECM composition and method for treating tissue bleeding and edema. The soluble matrix can coat endothelial cells, fill the gaps in the endothelial cell layer, and increase tissue perfusion or reduce fluid entering the tissue through vaso-stimulatory effects.

[0053] The present invention provides soluble ECM compositions and methods for treating traumatic brain and other neurological injuries. The soluble matrix can treat endothelial cells to repair leaky blood vessels, restore endothelium-dependent dilation and nitric oxide production, and reduce inflammation and oxidative stress.

[0054] Intracoronary injection is an alternative approach to transendocardial injection. Intracoronary delivery may involve balloon angioplasty during the typical course of treatment for myocardial infarction (MI). Intracoronary injection allows the biomaterial to enter the infarcted area because it takes advantage of the leaky vasculature after acute MI [5]. In prior art formulations, the matrix material (MM) is composed of a soluble fraction and insoluble submicron particles (>800 nm), which are too large to pass through or attach to the leaky vasculature. As a result, a method was provided to at least partially isolate the soluble fraction, termed soluble MM (SolMM), which can pass through and / or coat the leaky vasculature and still form a hydrogel in vivo. Because SolMM is derived from MM, SolMM has similar therapeutic effects, including reduced cardiomyocyte apoptosis, angiogenesis, and reduced negative LV remodeling.

[0055] To facilitate the understanding of the present invention, several terms and abbreviations used herein are defined below.

[0056] When introducing elements of the present invention or a preferred embodiment(s) thereof, the articles "a," "an," "the," and "said" are intended to mean that there are one or more of the elements. The terms "comprising," "including," and "having" are intended to be inclusive and mean that there may be additional elements other than the listed elements.

[0057] When the term "and / or" is used in the context of a list of more than one item, it means that any one of the listed items may be used alone or in combination with any one or more of the listed items. For example, the phrase "A and / or B" is intended to mean one or both of A and B, i.e., A only, B only, or a combination of A and B. The phrase "A, B, and / or C" is intended to mean A only, B only, C only, a combination of A and B, a combination of A and C, a combination of B and C, or a combination of A, B, and C.

[0058] It will be understood that aspects and embodiments of the invention described herein include aspects and embodiments "consisting of" and / or "consisting essentially of".

[0059] It is understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Thus, the description of a range should be considered to have specifically disclosed all possible subranges and individual numerical values ​​within that range. For example, the description of a range such as 1-6 should be considered to have specifically disclosed subranges such as 1-3, 1-4, 1-5, 2-4, 2-6, 3-6, etc., as well as individual numerical values ​​within that range, e.g., 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range. Also, herein, values ​​or ranges may be expressed as "about," "about" from one particular value, and / or "about" to another particular value. When such values ​​or ranges are expressed, other embodiments disclosed include the recited particular values ​​from the one particular value and / or to the other particular value. Similarly, when values ​​are expressed as approximations by use of the antecedent "about," it will be understood that the particular value forms another embodiment. It will be further understood that there are several values ​​disclosed herein, and that each value is also disclosed herein as "about" that particular value in addition to the value itself. In embodiments, "about" can be used to mean, for example, within 10% of the recited value, within 5% of the recited value, or within 2% of the recited value.

[0060] As used herein, the term "pharmaceutical composition" refers to a pharma- ceutically acceptable composition, which comprises a pharma- ceutically active agent, and in some embodiments, further comprises a pharma- ceutically acceptable carrier. In some embodiments, a pharmaceutical composition may be a combination of a pharma- ceutically active agent and a carrier.

[0061] The term "combination" refers to either a fixed combination in one dosage unit form or a kit of parts for combined administration, where one or more active compounds and combination partners (e.g., another drug, also referred to as a "therapeutic agent" or "adjunct agent", as described below) can be administered simultaneously and independently or separately within a time interval. In some circumstances, the combination partners exhibit a cooperative effect, e.g., a synergistic effect. Terms such as "co-administration" or "combined administration" as used herein are meant to encompass administration of selected combination partners to a single subject (e.g., patient) in need thereof, and are intended to include therapeutic regimens in which the drugs are not necessarily administered by the same route of administration or at the same time. The term "pharmaceutical combination" as used herein refers to a product obtained by mixing or combining two or more active ingredients, including those in which the combination of the active ingredients is fixed or not fixed. The term "fixed combination" means that both active ingredients, e.g., a compound and a combination partner, are administered to a patient at the same time in the form of a single entity or dose. The term "non-fixed combination" means that both active ingredients, e.g., a compound and a combination partner, are administered to a patient simultaneously, concurrently or sequentially as separate entities without specific time constraints, where such administration provides the two compounds in a therapeutically effective concentration in the patient's body. The latter also applies to cocktail therapy, e.g., the administration of three or more active ingredients.

[0062] As used herein, the term "pharmaceutical acceptable" means approved by a regulatory agency of the Federal or State government, or listed in the United States Pharmacopeia or other generally recognized pharmacopoeias, in addition to other formulations, for safe use in animals, and more specifically, in humans and / or non-human mammals.

[0063] As used herein, the term "pharmaceutical acceptable carrier" refers to excipients, diluents, preservatives, solubilizers, emulsifiers, adjuvants, and / or vehicles administered with the demethylenated compound(s). Such carriers may be sterile liquids, such as water and oils, including oils of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, polyethylene glycol, glycerin, propylene glycol, or other synthetic solvents. Antibacterial agents, such as benzyl alcohol or methylparaben; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; and agents for adjusting tonicity, such as sodium chloride or dextrose, may also be carriers. Methods of combining carriers to create compositions are known to those skilled in the art. In some embodiments, the term "pharmaceutical acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, isotonic agents, and absorption delaying agents, etc., compatible with pharmaceutical administration. The use of such media and agents for pharma- ceutical active substances is well known in the art.See, for example, Remington, The Science and Practice of Pharmacy, 20th ed., (Lippincott, Williams & Wilkins 2003).Except insofar as any conventional media or agent is incompatible with the active compound, its use in the present compositions is contemplated.

[0064] As used herein, "therapeutically effective" refers to an amount of pharmacologic active compound(s) sufficient to treat or improve, or in some way alleviate, symptoms associated with disease and pathology. When used in relation to a method, the method is effective enough to treat or improve, or in some way alleviate, symptoms associated with disease or condition. For example, in relation to age-related eye disease, an effective amount is an amount that is sufficient to prevent or prevent the onset of the disease, or, if disease symptoms have begun, to alleviate, improve, stabilize, reverse, or delay the progression of the disease, or to reduce the pathological consequences of the disease. In either case, the effective amount may be given in a single dose or in divided doses.

[0065] As used herein, the terms "treat", "treatment", or "treating" encompass at least ameliorating symptoms associated with a disease in a patient, where amelioration is used in a broad sense, e.g., referring to at least a reduction in the severity of a parameter, such as a symptom, associated with the disease or condition being treated. Thus, "treatment" includes situations in which a disease, disorder, or pathological condition, or at least a symptom associated therewith, is completely inhibited (e.g., prevented from occurring) or stopped (e.g., terminated), such that the patient no longer suffers from the condition, or at least the symptoms that characterize the condition.

[0066] As used herein, unless otherwise specified, the terms "prevent", "preventing" and "prevention" refer to the prevention of the onset, recurrence or spread of a disease or disorder, or one or more symptoms thereof. In certain embodiments, these terms refer to treatment with or administration of a compound or dosage form provided herein, with or without one or more other additional active agent(s), prior to the onset of symptoms, particularly to subjects at risk of a disease or disorder provided herein. These terms encompass the inhibition or reduction of symptoms of a particular disease. In certain embodiments, subjects with a family history of a disease are potential candidates for a preventive regimen. In certain embodiments, subjects with a medical history of recurrent symptoms are also potential candidates for prevention. In this regard, the term "prevention" may be used interchangeably with the term "prophylactic treatment".

[0067] As used herein, unless otherwise specified, a "prophylactically effective amount" of a compound is an amount sufficient to prevent a disease or disorder or prevent its recurrence. A prophylactically effective amount of a compound refers to an amount of a therapeutic agent that alone or in combination with one or more other agent(s) provides a prophylactic benefit in the prevention of a disease. The term "prophylactically effective amount" can include an amount that improves overall prevention or improves the prophylactic effectiveness of another prophylactic agent.

[0068] As used herein, unless otherwise specified, the term "subject" is defined herein to include animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, etc. In certain embodiments, the subject is a human. The terms "subject" and "patient" are used interchangeably herein in reference to a mammalian subject, e.g., a human. EXAMPLES

[0069] Experiment 1 - Production and characterization of SolMM Myocardial matrix (MM) formulations can be generated based on a previously described protocol (Figure 1) [3]. Briefly, fresh hearts are harvested from pigs (approximately 30-45 kg) and the LV myocardium is isolated. Major blood vessels and connective tissue are removed, and the remaining tissue is separated into 5 mm sections. 3 Cut into small pieces less than 1 mm thick (Figure 1A). Decellularize the tissue in 1% (w / v) sodium dodecyl sulfate (SDS) for 4-5 days until the tissue is completely white, then rinse in water for an additional day to remove residual SDS (Figure 1B). The material is lyophilized and ground into a fine powder (Figure 1C), followed by partial enzymatic digestion for 48 h. The material is then neutralized and buffered to match in vivo conditions, yielding MM capable of thermally induced gelation (Figure 1D).

[0070] The MM is then centrifuged at 15,000 RCF at 4 °C to separate the soluble and insoluble fractions (Figure 1E). The supernatant is isolated from the insoluble pellet, and this supernatant is referred to as the soluble MM fraction (SolMM). The SolMM is then dialyzed and lyophilized to adjust the salt concentration and ratio to maintain physiological conditions of SolMM. The SolMM is then resuspended at a high concentration (16 mg / mL), passed through a 0.22 μm filter into a sterile container, lyophilized, weighed, and stored at -80 °C until needed. The SolMM is then resuspended in sterile water to the appropriate concentration, approximately 30 minutes prior to injection. This suspension can then be injected subcutaneously into a rat and gel within 5 minutes (Figure 1F, 10 mg / mL, 500 μL). The consistency of the material can be assessed by polyacrylamide gel electrophoresis for protein distribution, PicoGreen assay for DNA content, dimethylmethylene blue assay for sulfated glycosaminoglycan (sGAG) content, and methylene blue assay for SDS content. Due to the digestion process to generate MM and the resulting SolMM, accurate data cannot be obtained from mass spectrometry. However, PAGE shows an overlapping distribution of proteins between MM and SolMM, except for the high molecular weight proteins in SolMM (Figure 2, lane 4).

[0071] Experiment 2 - Hemocompatibility of SolMM with human blood The interaction between SolMM and human blood samples (n=4) is evaluated with SolMM at different dilutions (1:1, 1:2, 1:10) against human whole blood or platelet-rich plasma. 1:1 represents the highest possible ratio between blood and SolMM, while 1:10 represents the physiologically relevant dilution based on the volumetric flow rate of the coronary vasculature and the intended infusion rate (1 mL / min). Hemocompatibility is evaluated as previously described for MM [4]. Red blood cell aggregation is performed within 4 h of sampling in a Myrenne aggregometer (Myrenne GmbH) after adjusting the hematocrit to 45% with autologous plasma. Aggregation is evaluated after stasis (M0) or low shear rate (3 Hz; M1) and absorbance (800 nm) is measured for 5 s. Similarly, platelet aggregation is measured with isolated platelet-rich plasma in a Lumiaggregometer (Chrono-log). Using the same dilutions as above to samples for platelet-rich plasma, add high concentrations of coagulation cascade agonists (adenosine diphosphate, epinephrine, and collagen) (1:200 to 1:1000 dilutions) and measure platelet aggregation by absorbance (600-620 nm).

[0072] Results of 1:1 and 1:10 dilutions (material vs. human blood) suggest that SolMM is hemocompatible, as all values ​​are within the normal physiological range (Table 1). [Table 1]

[0073] Experiment 3 - Distribution, retention, and efficacy in a small animal ischemia-reperfusion model Using a myocardial ischemia-reperfusion model in Sprague Dawley rats (225-250 g) with MI, the left coronary artery is occluded for 45 min followed by reperfusion. Within 5 min after reperfusion, the aorta is clamped for approximately 15 s to simulate intracoronary infusion, and 200 μl of SolMM is injected into the LV lumen at concentrations of 6, 10, or 14 mg / mL. This forces the material into the coronary artery and distributes it to the infarcted myocardium

[12] . Hearts (n=2 per concentration) are isolated 60 min after injection to determine whether the material is first distributed and then retained in the heart, as non-gelled material is cleared from the heart within 1 h [5]. SolMM is conjugated with Alexa Fluor™ 568 N-hydroxysuccinimidyl ester (Invitrogen) to allow for fluorescence detection and analysis. Degradation is assessed by examining retention of material at optimal concentrations at 6, 12, and 24 hours, 2, 3, 4, and 5 days, and 1 week (n=2-3 per time point) after injection. Saline (n=3 per time point) is mixed with unconjugated Alexa Fluor™ 568 to serve as a control. Hearts are fresh frozen in OCT Tissue-Tek compound and sectioned in the short axis direction into 16 equally spaced regions (approximately 300 μm between regions), 4 slides per region in duplicate, with 10 μm per section. One slide per region is used for H&E to confirm infarction and one slide per region is used for fluorescence analysis of SolMM.

[0074] Using concentrations of 6, 10, and 14 mg / mL (n=2 per group), the distribution of the infarct area increases with concentration, as shown by a greater distribution of prelabeled gel and increased intensity of the infarct area (10 mg / mL shown in Figure 2) at 1 hour post-injection; however, based on the yield of SolMM production, 10 mg / mL will be used in future experiments. Resuspending SolMM at 16 mg / mL followed by filtration results in a concentration of approximately 10 mg / mL, making the yield particularly limited based on the filtration step described in experiment 1. Resuspension concentrations above 16 mg / mL typically do not pass through the filter.

[0075] Based on time-course histology, material was observed in infarcted hearts up to approximately 3 days after injection.

[0076] In a rat ischemia-reperfusion model, the left coronary artery was occluded for 35 min to simulate myocardial infarction. The heart was then reperfused and soluble matrix was infused through the coronary artery using an aortic cross-clamp model. Rats were imaged using magnetic resonance imaging 24 h and 5 weeks after infusion. Left ventricular (LV) volumes and ejection fractions are shown in Figure 5. Significantly preserved LV volumes (end systole and end diastole) were observed in saline-infused controls 24 h after infusion. Ejection fractions showed a trend toward increased over saline controls. After 5 weeks, matrix-infused LV volumes were also significantly reduced compared to saline-infused controls, indicating that matrix infusion attenuates negative left ventricular remodeling.

[0077] Experiment 4: Injectable extracellular matrix using a balloon-equipped injection catheter to repair the heart after myocardial infarction. After myocardial infarction, extracellular matrix was injected through cardiac vasculature (e.g., left anterior descending artery or left main artery) for targeted delivery using a balloon-equipped infusion catheter. Figure 4 shows the distribution and retention of soluble myocardial matrix (SolMM) 1 hour after intracoronary infusion in a porcine ischemia-reperfusion model using a balloon-equipped infusion catheter. Figure 4 (left) shows a macroscopic short-axis histology image of an infarcted porcine heart. The infarct is circled in blue grayscale. Figure 4 (right) shows the infarcted myocardium in red grayscale channel displaying SolMM microgels throughout the infarcted myocardium.

[0078] The associated organs (brain, kidney, liver, lung, spleen) were evaluated by a blinded histopathologist and showed no abnormal signs of ischemia or inflammation 1 hour after matrix injection (Table 2). No soluble matrix gel was observed in any of the associated organs, suggesting the targeting ability of the injectable matrix to ischemic tissues. [Table 2]

[0079] Experiment 5: The injectable matrix can be used as a scaffold to promote vascularization of ischemic or injured tissue. Figure 6 shows an increase in infarct arteriole density after matrix injection in a myocardial infarction model. Infarcts were imaged 5 weeks after injection in a rat ischemia-reperfusion model. Arterioles were identified by co-staining with alpha smooth muscle actin and isolectin and traced manually in ImageJ. Upregulation of angiogenic pathways is shown in Figure 6.

[0080] Experiment 6: The injectable matrix can be used as a scaffold to reduce cell apoptosis or necrosis in ischemic or injured tissue. Figure 7 shows the reduction of cardiomyocyte apoptosis after matrix injection in a myocardial infarction model. Infarct and infarct border zone were stained with α-actinin for cardiomyocytes and cleaved caspase 3 for apoptosis. Apoptotic cardiomyocytes were counted manually in ImageJ. The reduction in apoptosis may extend to other cell types, but is not limited to endothelial cells, immune cells, fibroblasts, neurons, and (myocardial) myocytes. The reduction in apoptosis / necrosis pathways is shown in Figure 9. As the upregulated reactive oxygen species (ROS) metabolic pathway is shown in Figure 8, the reduction in apoptosis may be explained by an increase in ROS metabolism.

[0081] Figures 8 and 9 show differential gene expression suggestive of repair pathways for injectable extracellular matrix therapeutics. RNA was isolated from left ventricular free wall tissue 1 and 3 days after matrix injection and ischemia-reperfusion injury. On day 1, angiogenesis and reactive oxygen species metabolic pathways were upregulated. On day 3, a decrease in apoptosis / necrosis and a decrease in fibrotic pathways were observed. Downregulation of LRG1 was associated with myocardial fibrosis, with a trend observed in the opposite direction. Saline injection was used as a control.

[0082] Experiment 7: Matrix injection can treat endothelial cell injury / dysfunction. Soluble matrix can coat endothelial cells to reduce reactive oxygen species damage, increase endothelial cell survival, and / or fill gaps in leaky vasculature following ischemic injury. Following ischemic injury and matrix injection, the soluble matrix was observed to coat the lumen of small blood vessels (capillaries / endothelial cells). Figure 10 shows the lumen of endothelial cells (green grayscale) coated with soluble matrix (red grayscale). Note that the matrix does not occlude the lumen. Additionally, Figure 11 shows that the soluble matrix overlaps with endothelial cells of large blood vessels but does not occlude the lumen. Hearts were imaged using confocal microscopy up to 24 hours after injection to simulate myocardial infarction.

[0083] Experiment 8: Injectable matrices can co-deliver drugs, growth factors, microRNA, or other therapeutic agents The soluble extracellular matrix composition has potential binding domains for growth factors, microRNAs, and other potential drugs or therapeutics. The injectable matrix can gel within the tissue after injection and can be used for sustained release of therapeutics.

[0084] FIG. 12 shows the retention of soluble ECM in infarcted tissue 24 hours after matrix injection in an ischemia-reperfusion model. From left to right, hearts were injected with saline, matrix bound with VivoTag750, trilysine bound with VivoTag750, and matrix bound with VivoTag750. 24 hours after injection, hearts were harvested and imaged on a Licor Odyssey. In contrast to saline and trilysine injected hearts, matrix injected hearts showed greater signal intensity. Trilysine with VivoTag750 was used as a small peptide control and showed no appreciable retention.

[0085] Figure 13 shows the nanofiber structure of the soluble matrix hydrogel. A 10 mg / ml pregel solution was subcutaneously injected into the back of a rat, which then formed a gel and was taken for scanning electron microscope imaging. The gel structure is reminiscent of the natural extracellular matrix.

[0086] Experiment 9: Dynamic light scattering analysis shows the difference between MM and SolMM. FIG. 14 shows the dynamic light scattering data for soluble matrix (SolMM) and complete matrix (MM) at 1:50 dilution (1.0 mg / ml and 0.6 mg / ml, respectively), showing that the soluble matrix particles are less than 100 nm in diameter, while the complete matrix has larger particles.

[0087] FIG. 15 shows dynamic light scattering data for the soluble matrix (SolMM) at 1:10 and 1:100 dilutions (1.0 mg / ml and 0.1 mg / ml, respectively), indicating particles less than 100 nm in diameter.

[0088] FIG. 16 shows the absorbance (left) and transmittance (right) of saline, soluble matrix (SolMM), and complete matrix (MM).

[0089] FIG. 17 shows the relative absorbance (left) and transmittance (right) of the soluble matrix (SolMM) and the complete matrix (MM).

[0090] References [1]Benjamin et al.,American Heart Association Statistics,ObotAHASCStroke Statistics Subcommittee,S.Stroke,Heart Disease and Stroke Statistics-2017 Update:A Report From the American Heart Association,Circulation 135(10)(2017)e146-e603. [2]Singelyn,et al.,Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering,Biomaterials 30(29)(2009) 5409-16. [3]Singelyn,et al.,Catheter-deliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction,Journal of the American College of Cardiology 59(8)(2012)751-63. [4]Seif-Naraghi,et al.,Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction,Science translational medicine 5(173)(2013)173ra25. [5]Nguyen,et al.,Enzyme-Responsive Nanoparticles for Targeted Accumulation and Prolonged Retention in Heart Tissue after Myocardial Infarction,Advanced Materials 27(37)(2015)5547-5552. [6]Wassenaar,et al.,Evidence for mechanisms underlying the functional benefits of a myocardial matrix hydrogel for post-MI treatment,Journal of the American College of Cardiology 67(9)(2016)1074-86. [7]Schuster,et al.,Expansion of transmural myocardial infarction:a pathophysiologic factor in cardiac rupture,Circulation 60(7)(1979)1532-1538. [8]Arsenos,et al.,Arrhythmic sudden cardiac death:substrate,mechanisms and current risk stratification strategies for the post-myocardial infarction patient,Hellenic J Cardiol 54(4)(2013) 301-315. [9] Leor,et al.,Intracoronary Injection of In Situ Forming Alginate Hydrogel Reverses Left Ventricular Remodeling After Myocardial Infarction in Swine,Journal of the American College of Cardiology 54(11)(2009)1014-1023.

[10] Frey,et al.,Intracoronary delivery of injectable bioabsorbable scaffold(IK-5001)to treat left ventricular remodeling after ST-elevation myocardial infarction:A first-in-man study,Circulation:Cardiovascular Interventions 7(6)(2014)806-812.

[11] Spang,et al.,Extracellular matrix hydrogel therapies:In vivo applications and development,Acta Biomater.68(2018)1-14.

[12] Cheng,et al.,Magnetic enhancement of cell retention,engraftment,and functional benefit after intracoronary delivery of cardiac-derived stem cells in a rat model of ischemia / reperfusion,Cell transplantation 21(6)(2012)1121-35.

[13] Rane,et al.,Increased infarct wall thickness by a bio-inert material is insufficient to prevent negative left ventricular remodeling after myocardial infarction,PloS one 6(6)(2011)e21571.

[14] Conesa,et al.,A survey of best practices for RNA-seq data analysis,Genome biology 17 (2016)13-13.

[15] Costa-Silva,et al.,RNA-Seq differential expression analysis:An extended review and a software tool,PLOS ONE 12(12)(2017)e0190152-e0190152.

[16] Wang,et al.,Humanized mouse model for assessing the human immune response to xenogeneic and allogeneic decellularized biomaterials,Biomaterials 129(2017)98-110.

[17] Sonnenberg,et al.,Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarction,Biomaterials 45 (2015)56-63.

[18] Seif-Naraghi,et al.,Injectable extracellular matrix derived hydrogel provides a platform for enhanced retention and delivery of a heparin-binding growth factor,Acta Biomater.8(10)(2012)3695-703.

[19] van den Akker,et al.,Intramyocardial stem cell injection:go(ne)with the flow,European heart journal(2016)ehw056-ehw056.

[20] Wassenaar,et al.,Modulating in vivo degradation rate of injectable extracellular matrix hydrogels,J.Mater.Chem.B 4(16)(2016)2794-2802.

[21] Grover,et al.,Myocardial matrix-polyethylene glycol hybrid hydrogels for tissue engineering,Nanotech.25(1)(2014)014011.

[22] Gallet,et al.,Exosomes secreted by cardiosphere-derived cells reduce scarring,attenuate adverse remodelling,and improve function in acute and chronic porcine myocardial infarction,European Heart Journal 38(3)(2016)ehw240-ehw240.

[23] Dawn,et al.,Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium,and improve cardiac function,Proceedings of the National Academy of Sciences 102(10)(2005)3766-3771.

[24] Gallet,et al.,Intracoronary delivery of self-assembling heart-derived microtissues(cardiospheres)for prevention of adverse remodeling in a pig model of convalescent myocardial infarction,Circ Cardiovasc Interv.8(5).(2015)e002391.doi:10.1161 / CIRCINTERVENTIONS.115.002391-e002391.doi:10.1161 / CIRCINTERVENTIONS.115.002391.

[25] Bolli,et al.,Intracoronary Delivery of Autologous Cardiac Stem Cells Improves Cardiac Function in a Porcine Model of Chronic Ischemic Cardiomyopathy,Circulation 128(2)(2013)122-131.

[26] McKay,Raymond G.,et al,“Left ventricular remodeling after myocardial infarction:a corollary to infarct expansion.”Circulation 74, no.4(1986):693-702.

[27] Harpster,Mark H.,et al.“Earliest changes in the left ventricular transcriptome post-myocardial infarction.”Mammalian genome 17,no.7 (2006):701-715.

Claims

1. 1. A method for preparing a soluble extracellular matrix (ECM) composition, comprising: a. digesting the decellularized ECM material with an acid protease; b. neutralizing the digested ECM material in a liquid to a pH of 7.0-8.0; c. processing the liquid ECM to generate soluble and insoluble fractions; d. separating at least a portion of the soluble fraction from the insoluble fraction to obtain a soluble ECM composition.

2. 10. The method of claim 1, wherein processing the liquid ECM to generate the soluble and insoluble fractions is performed by centrifugation.

3. 2. The method of claim 1, wherein processing the liquid ECM to generate the soluble and insoluble fractions is performed by dialysis or filtration.

4. The method of claim 1 , wherein the separation is performed using an exclusion filter with a size of 250 nm or less.

5. The method of claim 1 , wherein the soluble ECM composition is further lyophilized and rehydrated.

6. A soluble ECM composition comprising decellularized, digested and neutralized tissue from which at least a portion of the solid ECM material has been removed, said soluble ECM composition passing through a 250 nm size exclusion filter.

7. The soluble ECM composition of claim 6 , wherein the composition is formulated for intravascular injection.

8. The soluble ECM composition of claim 6 , wherein the composition is liquid at room temperature and forms a gel after infusion or injection in vivo.

9. 7. The soluble ECM composition of claim 6, wherein the composition is liquid at room temperature and forms a coating that lines damaged blood vessels after infusion or injection in vivo.

10. The soluble ECM composition of claim 6 , wherein the composition is liquid at room temperature and fills pores between endothelial cells after infusion or injection in vivo.

11. The soluble ECM composition of claim 6 , derived from human, animal, embryonic, or fetal tissue.

12. The soluble ECM composition of claim 6, derived from heart, brain, bladder, small intestine, or skeletal muscle tissue, kidney, liver, lung, and blood vessels.

13. A method of treating a subject to promote tissue repair, comprising administering to a subject in need thereof an infusion of an effective amount of the soluble ECM composition of claim 6.

14. 14. The method of claim 13, wherein the infusate is delivered intravenously or intravascularly via a catheter.

15. The method of claim 13 , wherein the soluble ECM composition forms a gel within a tissue when delivered in vivo.

16. The method of claim 13, wherein the soluble ECM composition is crosslinked with glutaraldehyde, formaldehyde, a bis-NHS molecule, or other crosslinking agent prior to administration.

17. 14. The method of claim 13, wherein the soluble ECM composition is combined with cells, peptides, proteins, DNA, drugs, nanoparticles, nutrients, survival-promoting additives, proteoglycans, and / or glycosaminoglycans prior to administration.

18. 14. The method of claim 13, wherein the soluble ECM composition is combined and / or crosslinked with a synthetic polymer or a biologically derived material prior to administration.

19. The method of claim 13, wherein the soluble ECM composition induces endogenous cell growth, angiogenesis, and regeneration in the subject.

20. The method of claim 13 , wherein the soluble ECM composition promotes cell survival and reduces inflammation in the subject.

21. A method for treating acute myocardial infarction, comprising injecting or infusing into a subject in need thereof an effective amount of a soluble ECM composition comprising decellularized, digested and neutralized tissue from which at least a portion of the solid ECM material has been removed.

22. 22. The method of claim 21, wherein the composition is delivered intravascularly.

23. 22. The method of claim 21, wherein the composition is delivered using a balloon infusion catheter.

24. 22. The method of claim 21, wherein the composition transitions into a gel form within tissue after delivery.

25. 22. The method of claim 21, wherein the composition is liquid at room temperature and forms a coating that lines the infarcted blood vessel after delivery.

26. 22. The method of claim 21, wherein the composition is liquid at room temperature and fills the pores between infarct endothelial cells after delivery.

27. The method of claim 21, wherein the composition degrades within 1 to 14 days after injection or infusion.

28. 22. The method of claim 21, wherein injection or infusion of the composition repairs damage to the myocardium sustained by the subject.

29. 22. The method of claim 21, wherein injection or infusion of the composition repairs damage caused by ischemia in the subject.

30. 22. The method of claim 21, wherein the effective amount is an amount that increases blood flow, increases viable tissue mass, or induces new blood vessel formation in the area of ​​the injection or infusion in the subject.

31. A method for treating endothelial cell injury and / or dysfunction, comprising injecting or infusing into a subject in need thereof an effective amount of a soluble ECM composition comprising decellularized, digested and neutralized tissue from which at least a portion of the solid ECM material has been removed.

32. 32. The method of claim 31, wherein the effective amount promotes endothelial cell survival, proliferation, or vasculogenesis, and / or reduces inflammation, apoptosis, reactive oxygen species damage, or leaky vasculature.

Citation Information

Patent Citations

  • Biocompatible Solubilized Scaffold Extract Derived from Decellularized Organ Tissue, Method for Preparating the Biocompatible Scaffold Extract and Uses for Thereof

    KR101628821B1

  • Extracellular matrix (ECM) hydrogel and soluble fraction thereof for the treatment of cancer

    WO2018161034A1